Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7332893 | 0.87 | ALDH1A1 (0.56) | ALDH1A1MAPK1L3MBTL1SYKKMT2A | |
| SCHEMBL23023517 | 0.86 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1SYKKMT2A | |
| SCHEMBL10276827 | 0.86 | MEN1 (0.49) | ALDH1A1MAPK1L3MBTL1SYKKMT2A | |
| SCHEMBL16761858 | 0.86 | SYK (0.49) | ALDH1A1MAPK1L3MBTL1SYKKMT2A | |
| SCHEMBL2141676 | 0.86 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1SYKKMT2A | |
| SCHEMBL294341 | 0.86 | ALDH1A1 (0.73) | ALDH1A1MAPK1L3MBTL1KMT2ASLC6A2 | |
| SCHEMBL12990128 | 0.84 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1SYKKMT2A | |
| SCHEMBL22481266 | 0.84 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1SYKKMT2A | |
| SCHEMBL8069055 | 0.84 | ALDH1A1 (0.70) | ALDH1A1MAPK1L3MBTL1KMT2ASLC6A2 | |
| SCHEMBL20094984 | 0.83 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1SYKKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612394-B2 | Herbicidal malonamides | BASF SE (DE) | 2026-04-28 | — | — | US | disclosed |
| US-12534453-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| EP-4604986-A2 | LONG-ACTING NATRIURETIC PEPTIDES AND USES THEREOF | Eli Lilly and Company (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2025080946-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20240383886-A1 | Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof | ABBVIE INC. | 2024-11-21 | — | — | US | disclosed |
| US-20240247042-A1 | GLUCAGON LIKE PEPTIDE COMPOUNDS | NOVARTIS AG (CH) | 2024-07-25 | — | — | US | disclosed |
| US-20240246939-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2024-07-25 | — | — | US | disclosed |
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240174727-A1 | LONG-ACTING NATRIURETIC PEPTIDES AND USES THEREOF | ELI LILLY AND COMPANY | 2024-05-30 | — | — | US | disclosed |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| WO-1995033731-A1 | HYDROXAMIC ACID DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 1995-12-14 | — | — | WO | disclosed |
| EP-0684240-A1 | Hydroxamic acid derivatives with tricyclic substitution | F. HOFFMANN-LA ROCHE AG (CH) | 1995-11-29 | — | — | EP | disclosed |
| EP-0575844-A2 | Hydroxamic acid derivatives and pharmaceutical compositions thereof | F. HOFFMANN-LA ROCHE AG (CH) | 1993-12-29 | — | — | EP | disclosed |
| US-5192800-A | Hypotensive agents | PFIZER INC. (US) | 1993-03-09 | — | — | US | disclosed |
| EP-0274234-B1 | SPIRO-SUBSITUTED GLUTARAMIDE DIURETIC AGENTS | Pfizer Limited (GB) | 1991-09-11 | — | — | EP | disclosed |
| US-5030654-A | Glutaramide diuretic agents | PFIZER INC. (US) | 1991-07-09 | — | — | US | disclosed |
| EP-0274234-A2 | Spiro-subsituted glutaramide diuretic agents | Pfizer Limited (GB) | 1988-07-13 | — | — | EP | disclosed |
| EP-0224088-A2 | Process for the solid-phase synthesis of retro-inverso peptides | ENIRICERCHE S.p.A. (IT) | 1987-06-03 | — | — | EP | disclosed |
| US-4277395-A | OF ELASTASE; OLIGOPEPTIDES | RICHARDSON-MERRELL INC. (US) | 1981-07-07 | — | — | US | disclosed |
| EP-0021883-A2 | N-acyl-amino acid derivatives and pharmaceutical compositions containing them, intermediates and starting compounds | MERRELL TORAUDE ET COMPAGNIE (FR) | 1981-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383886-A1 | Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof | PTPN5, PTPN1, PTPN2 | ALDH1A1 2836/4885MAPK1 823/4885L3MBTL1 3666/4885 |
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | FASN, FABP1, SCD | ALDH1A1 634/4885MAPK1 4777/4885L3MBTL1 2573/4885 |
| US-12612394-B2 | Herbicidal malonamides | CBR3, DDT, HACL2 | ALDH1A1 280/4885MAPK1 1102/4885L3MBTL1 169/4885 |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | ALDH1A1 2537/4885MAPK1 2690/4885L3MBTL1 2977/4885 |
| US-12534453-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS1, GYS2, GBA1 | ALDH1A1 2276/4885MAPK1 1858/4885L3MBTL1 656/4885 |
| US-20240174727-A1 | LONG-ACTING NATRIURETIC PEPTIDES AND USES THEREOF | NPPA, NPR1, NPR3 | ALDH1A1 3581/4885MAPK1 3739/4885L3MBTL1 3167/4885 |
| US-20240247042-A1 | GLUCAGON LIKE PEPTIDE COMPOUNDS | GLP1R, IAPP, GPR119 | ALDH1A1 3655/4885MAPK1 1253/4885L3MBTL1 1885/4885 |
| US-20240246939-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | GYS2, GYS1, PYGL | ALDH1A1 2458/4885MAPK1 652/4885L3MBTL1 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.